The funding round was led by angel investor Robert Williams and supported by the Development Bank of Wales.
"Pelly bridges the gap between data and action. We’ve built a platform that leverages AI to turn complex data into clear, actionable insights for clubs. Our focus is empowering teams to operate with agility, integrating the data they already have, and providing tools that help them win—both on and off the pitch. We’ve been working closely with international academic institutions to develop our prototype. Over 100 industry professionals have been consulted to date, and eight football clubs are now testing the product before going to market in the next few months. The support of our team, advisors, and investors is helping us to accelerate our growth. They’re encouraging us to work smarter whilst opening doors and providing the working capital that we need to fund our early-stage development. It’s a huge vote of confidence in us, our business model, and our potential as a young and driven team."
Leading US and UK banks back the financial data standardization platform to modernise business lending.
"This strategic investment from two of the world’s leading banks validates our vision of making standardized accounting data the cornerstone of modern lending."
The financing was secured without venture capital backing to advance product development and upcoming video analysis tools.
"We're honoured to welcome Professor Michael to our advisory board. His unmatched expertise in the field of AI will be invaluable as we continue to develop and improve our AI-native offering."
The investment comes from FPE Fund III and will support Clearstate as it expands its geographical reach and go to market capabilities.
"Clearstate is a highly compelling business that aligns perfectly with FPE’s expertise in supporting B2B data and information companies. Operating in a large and dynamic market, Ivy and her team have built Clearstate into a leading provider of essential market data. We are genuinely excited to partner with Ivy and her team, supporting their vision and helping to unlock the significant growth potential ahead."
"The widespread success of GLP-1s for weight management has certainly changed the management landscape in obesity, but high discontinuation rates mean that they represent an imperfect solution to a complex issue. With the funding secured in this round, we will be able to significantly progress our path to clinic for DBL’s lead candidates which target greater fat vs muscle loss and provide a much-required alternative to GLP-1s for the majority of users forced to discontinue GLP-1s due to intolerance."
